MDM is committed to successfully developing, analyzing, and communicating scientifically-defensible health and economic value messages for our client’s external and internal stakeholders. MDM provides a wide range of global health outcomes research services with a focus on pharmacoeconomic modeling (including target market segment identification and quality control audits), reimbursement dossiers, systematic literature reviews, and database and statistical analyses. MDM incorporated in 1997 (its predecessor, Smolen & Associates, was founded in 1994).

MDM has performed research in over eighty distinct diseases or disorders encompassing work for pharmaceutical, biotechnology, device and diagnostic companies, as well as academic medical research centers. Through 2015, MDM’s work has been or is being successfully implemented in 24 countries (Australia, Brazil, Canada, China, Colombia, The Czech Republic, France, Germany, Great Britain, Hong Kong, Hungary, Italy, Japan, Mexico, The Netherlands, Poland, Russia, Scotland, South Korea, Spain, Sweden, Taiwan, Turkey, and the US). The senior research team at MDM averages over twenty years of modeling and health outcomes research experience and over ten years of tenure at the company. MDM strives to build long-term partner relationships by providing an insightful, responsive, and flexible approach to addressing our global clients’ increasingly complex needs.